Letters

OBSERVATION

Pathologically Confirmed Chronic Traumatic Encephalopathy in a 25-Year-Old Former College Football Player

Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repetitive head impacts.[1] Presently, CTE only can be diagnosed pathologically; however, research efforts, such as the ongoing Understanding Neurological Injury and Traumatic Encephalopathy (UNITE) Study,[2] are investigating ways to diagnose CTE during life. As part of the UNITE Study, a panel of clinicians, blinded to neuropathology, make retrospective clinical consensus diagnoses using published criteria, including proposed clinical research criteria for CTE.[3] Here, we present an informative case from the UNITE Study.

Editorial page 263

Report of a Case | A 25-year-old man with a congenital bicuspid aortic valve and a family history of addiction and depression died of cardiac arrest secondary to *Staphylococcus aureus* endocarditis. He played American football for 16 years, beginning at age 6 years, including 3 years of Division I college football (red shirt, freshman, and sophomore) as a defensive linebacker and special teams player. He experienced more than 10 concussions, all while playing football, the first occurring at age 8 years and none resulting in hospitalization. During his freshman year of college, he had a concussion with momentary loss of consciousness followed by ongoing headaches, neck pain, blurry vision, tinnitus, insomnia, anxiety, and difficulty with memory and concentration. When he returned to play after a few days, symptoms persisted. A neurologist prescribed cyclobenzaprine and topiramate, which offered limited benefit. He stopped playing football at the beginning of his junior season owing

Table. Neuropsychological Testing[a]

Test	Score[b]	Interpretation[c]
Intellectual functioning		
WAIS-III/7		
Estimated visual IQ	102	Average
Estimated performance IQ	100	Average
Estimated full-scale IQ	101	Average
WTAR	103	Average
Memory		
WMS-III		
Logical memory I	8	Low average
Logical memory II	8	Low average
CVLT-II		
Total trials 1-5	22	Impaired
Trial 1	4	Borderline
Trial 5	4	Impaired
Short-delay free recall	5	Impaired
Short-delay cued recall	5	Impaired
Long-delay free recall	4	Impaired
Long-delay cued recall	5	Impaired
BVMT-R		
Trial 1	8	Average
Trial 2	10	Average
Trial 3	11	Average
Delayed recall	11	Average
Language		
BNT-2	47	Impaired
D-KEFS letter fluency	26	Low average
D-KEFS category fluency	32	Average
Attention/executive functioning		
TMT		
Part A speed (errors)	14 s(0)	High average
Part B speed (errors)	84 s(1)	Impaired
Symbol digit modalities test		
Written	36	Impaired
Oral	57	Low average
Stroop color and word test		
Word score	46	Average
Color score	46	Average
Color-word score	51	Average
Interference	53	Average
Visuospatial		
Rey figure copy	8	Low average
BVMT-R copy	12	Within expectation
Judgment of line orientation	28	High average

Abbreviations: BNT, Boston Naming Test; BVMT-R, Brief Visuospatial Memory Test–Revised; CVLT, California Verbal Learning Test; D-KEFS, Delis-Kaplan Executive Function System; TMT, Trail Making Test; WAIS, Wechsler Adult Intelligence Scale; WMS, Wechsler Memory Scale; WTAR, Wechsler Test of Adult Reading.

[a] Summary: Intelligence was average and reading ability was commensurate. Visuospatial abilities were average. There were deficits in verbal episodic encoding, although verbal episodic retrieval and visual memory were intact. There were deficits in set-shifting and processing speed. Selective attention was intact. There were deficits in naming. Letter and category fluency were intact.

[b] All scores are raw, unless otherwise indicated.

[c] Interpretations are based on normative data accounting for age and education level. Percentile conversions are as follows: very superior >98%; superior, 91%-97%; high average, 75%-90%; average, 25%-74%; low average, 9%-24%; borderline, 2%-8%; and impaired <2%.

(continued)

Figure. Neuropathological Findings of Chronic Traumatic Encephalopathy (CTE)



A, The brain showed mild ventricular dilation and hippocampal atrophy. Pathological lesions of hyperphosphorylated tau (ptau) consisting of neurofibrillary tangles, neurites, and astrocytes around small blood vessels were found at the sulcal depths of the frontal and temporal lobes. Free-floating 50-µm section immunostained for AT8 (B) and paraffin-embedded 10-µm section immunostained for AT8 (C; original magnification ×200). These ptau lesions are considered to be pathognomonic for CTE based on the preliminary National Institute of Neurological Disorders and Stroke consensus criteria for the pathological diagnosis of CTE.[1,5,6] Characteristic CTE ptau pathology was also found in the parietal lobes, entorhinal cortex, anterior hippocampus, hypothalamus, nucleus basalis of Meynert, substantia nigra, locus coeruleus, and median raphe. There was no immunopositivity for amyloid-β, TAR DNA-binding protein 43, or α-synuclein.

to ongoing symptoms. He began failing courses despite having earned above-average grades in high school (3.8 GPA) and earlier in college. He left school with a GPA of 1.9, 12 credits short of earning his bachelor degree.

His symptoms persisted and included apathy, anhedonia, decreased appetite, hypersomnia, feelings of worthlessness, and passive suicidal ideations. He had difficulty maintaining a job and eventually stopped seeking employment. He began using marijuana daily to alleviate headaches and anxiety and to improve sleep. At age 23 years, he became verbally and physically abusive toward his wife, a change from his prior demeanor. At age 24 years, he underwent neuropsychological evaluation (**Table**). He became increasingly dependent on his wife, although basic activities of daily living remained intact.

His next of kin provided written informed consent for participation and brain donation. Institutional review board approval for brain donation was obtained through the Boston University Alzheimer's Disease Center and CTE Program and the Bedford VA Hospital. Institutional review board approval for postmortem clinical record review, interviews with family members, and neuropathological evaluation was obtained through the Boston University School of Medicine.

Consensus members unanimously supported postconcussive syndrome (PCS) as the primary diagnosis, with possible CTE and major depression as contributing diagnoses. Although CTE was considered, the lack of delay in symptom onset, his young age, and his family history of depression reasoned against CTE as the primary diagnosis. Consensus members thought that neuropsychological performance, while impaired, did not discriminate postconcussive syndrome or major depression from CTE (**Figure**).

Discussion | Focal lesions of CTE have been found in athletes as young as 17 years[1]; however, widespread CTE pathology, as found in this case, is unusual in such a young football player. Although idiopathic depression and postconcussive syndrome commonly present in a similar fashion,[4] the presence of widespread CTE pathology argues against but does not exclude them as potential etiologies of the clinical syndrome. While the case suggests that CTE should be considered in the differential diagnosis of a young adult with extensive repetitive head impact exposure and persistent mood and behavioral symptoms, it does not allow us to infer the likelihood of CTE in this setting.

While proposed clinical research criteria for CTE include impairment in memory and executive function on neuropsychological testing,[3] to our knowledge, this is the first published case of pathologically confirmed CTE to include a neuropsychological test profile. It remains to be determined whether impairment in learning and executive function with preserved verbal episodic retrieval is a common presentation of CTE.

Studies of clinicopathological correlation, such as the UNITE Study,[2] should help identify clinical features that are sensitive and specific for CTE pathology. Prospective studies that include neuropsychological testing with imaging and fluid biomarkers will be essential to future improvements in diagnosis of CTE during life.

Jesse Mez, MD, MS
Todd M. Solomon, PhD
Daniel H. Daneshvar, MA
Thor D. Stein, MD, PhD
Ann C. McKee, MD

Author Affiliations: Alzheimer's Disease Center, Chronic Traumatic Encephalopathy Program, Boston University School of Medicine, Boston, Massachusetts (Mez, Solomon, Daneshvar, Stein, McKee); Department of Neurology, Boston University School of Medicine, Boston, Massachusetts (Mez, McKee); Concussion Legacy Foundation, Waltham, Massachusetts (Daneshvar); US Department of Veterans Affairs, VA Boston Healthcare System, Jamaica Plain, Massachusetts (Stein, McKee); US Department of Veterans Affairs Medical Center, Bedford, Massachusetts (Stein, McKee); Department of Pathology, Boston University School of Medicine, Boston, Massachusetts (Stein, McKee).

Corresponding Author: Ann C. McKee, MD, Boston University School of Medicine, 72 E Concord St, B7800, Boston, MA 02118 (amckee@bu.edu).

Published Online: January 4, 2016. doi:10.1001/jamaneurol.2015.3998.

Conflict of Interest Disclosures: None reported.

Funding/Support: This design and conduct of the study were supported by the National Institute of Neurological Disorders and Stroke (grants 1UO1NS086659-01, RO1NS078337, and R56NS078337), Department of Defense (grant W81XWH-13-2-0064), Department of Veterans Affairs, the Veterans Affairs Biorepository (grant CSP 501), the National Institute of Aging, Boston University Alzheimer's Disease Center (grant P30AG13846; supplement 0572063345-5), Department of Defense Peer Reviewed Alzheimer's Research Program (DoD- PRARP grant 13267017), the National Institute on Aging–Boston University Framingham Heart Study (grant RO1AG1649), the National Operating Committee on Standards for Athletic Equipment, and the Sports Legacy Institute. The collection and management of data were also supported by unrestricted gifts from the Andlinger Foundation, the WWE (World Wrestling Entertainment), and the National Football League.

Role of the Funder/Sponsor: The funders had a role in the design and conduct of the study but not the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Patrick T. Kiernan, BA, Lauren Murphy, BA, Philip H. Montenigro, BS, Victor E. Alvarez, MD, Lee E. Goldstein, MD, PhD, Douglas I. Katz, MD, Neil W. Kowall, MD, Robert C. Cantu, MD, and Robert A. Stern, PhD, of Boston University School of Medicine and Lisa McHale, BA, of the Concussion Legacy Foundation. Mr Kiernan conducts retrospective clinical interviews and participates in patient recruitment; Ms Murphy participates in patient recruitment; Mr Montenigro conducts retrospective clinical interviews; Dr Alvarez participates in pathological diagnosis; and Ms McHale participates in patient recruitment. They also made substantial contributions to study conception and design and drafting and critically revising the manuscript for important intellectual content. Mr Kiernan, Ms Murphy, and Dr Alvarez received compensation for their contributions. Drs Goldstein, Katz, Kowall, Cantu, and Stern participate in clinical consensus diagnosis and made substantial contributions to conception and design and critically revising the manuscript for important intellectual content. Compensation was received for such contributions. We gratefully acknowledge the use of the resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, Massachusetts). We also gratefully acknowledge the help of all members of the Chronic Traumatic Encephalopathy Program at Boston University School of Medicine, the Boston VA, as well as the individuals and families whose participation and contributions made this work possible. We also thank the patient's next of kin for granting permission to publish this information.

1. McKee AC, Stein TD, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. *Brain*. 2013;136(pt 1):43-64. doi:10.1093/brain/aws307.

2. Mez J, Solomon TM, Daneshvar DH, et al. Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE Study. *Alzheimers Res Ther*. 2015;7(1):62.

3. Montenigro PH, Baugh CM, Daneshvar DH, et al. Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. *Alzheimers Res Ther*. 2014;6(5):68.

4. Broshek DK, De Marco AP, Freeman JR. A review of post-concussion syndrome and psychological factors associated with concussion. *Brain Inj*. 2015;29(2):228-237.

5. McKee AC, Cairns NJ, Dickson DW, et al. The First NINDS/NIBIB Consensus Meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. *Acta Neuropathologica*. In press.

6. Shen H. Researchers seek definition of head-trauma disorder. *Nature*. 2015;518(7540):466-467.

Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod

A 62-year-old woman with multiple sclerosis treated with fingolimod for 3 years presented to the clinic with a tender nodule on her forehead, which had gradually grown over 3 weeks (**Figure**). She reported bumping her forehead on an air-conditioning unit several months prior. She denied fever, neck stiffness, and photophobia, and her neurological examination was at her baseline. She lived alone with a pet cat and spent minimal time outdoors. She had no recent exposure to systemic steroids.

A shave biopsy of the skin revealed granulomatous inflammation composed of histiocytes, giant cells, and lymphocytes admixed with numerous narrow-budding yeasts with thick capsules. Tissue culture grew *Cryptococcus neoformans*. A full workup for systemic disease, including chest radiography, serum and cerebrospinal fluid cryptococcal antigen, and blood and cerebrospinal fluid cultures, was negative. A human immunodeficiency virus test result was negative. She had regular monitoring of her T-cell counts while receiving fingolimod, most recently showing a white blood cell count of 3.9/μL (4000-1100/μL [to convert to $\times 10^9$ per liter, multiply by .001]); lymphocyte count of 0.65/μL (range, 1000-5000/μL [to convert to $\times 10^9$ per liter, multiply by .001]); absolute CD4 count of 56/μL (range, 560-1840/μL); and CD8 count of 121/μL (range, 260-1230/μL). She had no other lesions on full-body skin examination.

Given the absence of systemic findings, the patient was diagnosed as having primary cutaneous cryptococcosis (PCC) and treated with a loading dose of 800 mg fluconazole, followed by 400 mg daily until complete healing, for a minimum of 6 weeks. Fingolimod was discontinued during workup for disseminated infection and was not restarted because the patient had a change in diagnosis from relapsing-remitting to secondary progressive multiple sclerosis. At 1-month follow up, the forehead lesion was healing with residual scar, and she remained in good health.

Discussion | Fingolimod is a disease-modifying treatment for multiple sclerosis, which acts via downregulation of sphingosine-1-phosphate receptors on lymphocytes, resulting in selective retention of $CCR7^+$ naive T cells and central memory T cells in lymphoid organs. There is less effect on $CCR7^-$ $CD8^+$ effector T cells, although there is evidence of